Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis

被引:68
|
作者
Quesada-Vazquez, Sergio [1 ]
Aragones, Gerard [2 ]
Del Bas, Josep M. [1 ]
Escote, Xavier [1 ]
机构
[1] Ctr Tecnol Catalunya, Unitat Nutr & Salut, Reus 43204, Spain
[2] Univ Rovira & Virgili, Nutrigen Res Grp, Dept Biochem & Biotechnol, E-43007 Tarragona, Spain
基金
欧盟地平线“2020”;
关键词
Non-Alcohol Fatty Liver Disease; gut microbiota; NAFLD; dysbiosis; bacterial translocation; INTESTINAL BACTERIAL OVERGROWTH; AKKERMANSIA-MUCINIPHILA; MURINE MODEL; OBESITY; ACID; BILE; STEATOHEPATITIS; FIBROSIS; ALCOHOL; INFLAMMATION;
D O I
10.3390/cells9010176
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease in the world. NAFLD is principally characterized by an excessive fat accumulation in the hepatocytes. Diet is considered as one of the main drivers to modulate the composition of gut microbiota, which participate in different processes, affecting human metabolism. A disruption in the homeostasis of gut microbiota may lead to dysbiosis, which is commonly reflected by a reduction of the beneficial species and an increment in pathogenic microbiota. Gut and liver are in close relation due to the anatomical and functional interactions led by the portal vein, thus altered intestinal microbiota might affect liver functions, promoting inflammation, insulin resistance and steatosis, which is translated into NAFLD. This review will highlight the association between diet, gut microbiota and liver, and how this axis may promote the development of NAFLD progression, discussing potential mechanisms and alterations due to the dysbiosis of gut microbiota. Finally, it will revise the variations in gut microbiota composition in NAFLD, and it will focus in specific species, which directly affect NAFLD progression.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Gut microbiota and non-alcoholic fatty liver disease
    Gkolfakis, Paraskevas
    Dimitriadis, George
    Triantafyllou, Konstantinos
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2015, 14 (06) : 572 - 581
  • [2] Gut microbiota and non-alcoholic fatty liver disease
    Paraskevas Gkolfakis
    George Dimitriadis
    Konstantinos Triantafyllou
    [J]. Hepatobiliary & Pancreatic Diseases International, 2015, 14 (06) : 572 - 581
  • [3] Gut microbiota and non-alcoholic fatty liver disease
    Abenavoli, Ludovico
    Procopio, Anna C.
    Scarpellini, Emidio
    Polimeni, Natale
    Aquila, Isabella
    Larussa, Tiziana
    Boccuto, Luigi
    Luzza, Francesco
    [J]. MINERVA GASTROENTEROLOGY, 2021, 67 (04): : 339 - 347
  • [4] Non-alcoholic fatty liver and the gut microbiota
    Bashiardes, Stavros
    Shapiro, Hagit
    Rozin, Shachar
    Shibolet, Oren
    Elinav, Eran
    [J]. MOLECULAR METABOLISM, 2016, 5 (09): : 782 - 794
  • [5] Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease
    Yang, Yao-Jong
    Ni, Yen-Hsuan
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 : S55 - S61
  • [6] Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease
    Zhou, Jin
    Tripathi, Madhulika
    Sinha, Rohit A.
    Singh, Brijesh Kumar
    Yen, Paul M.
    [J]. HEPATOMA RESEARCH, 2021, 7
  • [7] Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease
    Koukias, Nikolaos
    Buzzetti, Elena
    Tsochatzis, Emmanuel A.
    [J]. MINERVA ENDOCRINOLOGICA, 2017, 42 (02) : 184 - 194
  • [8] Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease
    Shen, Feng
    Zheng, Rui-Dan
    Sun, Xing-Qiang
    Ding, Wen-Jin
    Wang, Xiao-Ying
    Fan, Jian-Gao
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2017, 16 (04) : 375 - 381
  • [9] Gut microbiota and non-alcoholic fatty liver disease: new insights
    Aron-Wisnewsky, J.
    Gaborit, B.
    Dutour, A.
    Clement, K.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (04) : 338 - 348
  • [10] Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease
    Mouzaki, Marialena
    Bandsma, Robert
    [J]. CURRENT DRUG TARGETS, 2015, 16 (12) : 1324 - 1331